Cardiovascular Business July 26, 2024
Edwards Lifesciences has made a significant splash in the structural heart space, agreeing to acquire both JenaValve and Endotronix for a combined total of approximately $1.2 billion.
“These acquisitions expand our opportunities to address the unmet needs of aortic regurgitation and heart failure patients around the world,” Bernard Zovighian, Edwards’ CEO, said in a statement. “We are pleased to enter these structural heart therapeutic areas with innovation, world-class science and clinical evidence to provide access to life-saving technologies for patients around the world.”
In June, Edwards sold its critical care portfolio to BD (Becton, Dickinson and Company) for $4.2 billion in cash, highlighting its plan to double down on its commitment to new structural heart technologies; this pair of big-name...
Today's Sponsors
Today's Sponsor